Table 3.
Treatment and prognosis of patients with COVID in Guangzhou and Wuhan.
| Guangzhou#1 (N = 20) | Wuhan#2 (N = 99) | P value | |
|---|---|---|---|
|
Treatment | |||
| Oxygen therapy | 8 (40.0%) | 75 (75.8%) | 0.001 |
| Mechanical ventilation | 2 (10.0%) | 17 (17.2%) | 0.738 |
| Non-invasive (ie, face mask) | 1 (5.0%) | 13 (13.1%) | 0.460 |
| Invasive | 1 (5.0%) | 4 (4.0%) | 1.000 |
| CRRT | 0 (0.0%) | 9 (9.1%) | 0.354 |
| ECMO | 0 (0.0%) | 3 (3.0%) | 1.000 |
| Antiviral therapy | 16 (80.0%) | 75 (76.0%) | 0.781 |
| Kaletra* | 16 (80.0%) | NA | NA |
| Arbidol | 13 (65.0%) | NA | NA |
| Interferon alpha atomized inhalation | 5 (25.0%) | NA | NA |
| Ribavirin | 1 (5.0%) | NA | NA |
| Combination of two antiviral drugs | 9 (45.0%) | NA | NA |
| Combination of three antiviral drugs | 4 (20.0%) | NA | NA |
| Antibiotic therapy | 17 (85.0%) | 70 (70.7%) | 0.271 |
| Glucocorticoids | 5 (25.0%) | 19 (19.2%) | 0.550 |
| Intravenous immunoglobulin therapy | 6 (30.0%) | 27 (27.3%) | 0.789 |
| Thymosin alpha1 | 4 (20.0%) | NA | NA |
| Chinese traditional medicine |
20 (100.0%) |
NA |
NA |
|
SARS-CoV-2 RNA positive at admission | |||
| Nasopharyngeal swabs | 20 (100.0%) | 99 (100.0%) | 1.000 |
| Feces (n/N, %) |
4/7 (57.1%) |
NA |
NA |
|
Duration of SARS-CoV-2 RNA positive | |||
| Nasopharyngeal swabs (N = 20) (days) | 12.0 (7.5, 15.5) | NA | NA |
| Feces (N = 4 of 7) (range, days) |
4.0–16.0 |
NA |
NA |
|
Clinical outcome | |||
| Outcome | 0.005 | ||
| Remained in hospital | 6 (30.0%) | 57 (57.6%) | |
| Discharged | 14 (70.0%) | 31 (31.3%) | |
| Died | 0 (0.0%) | 11 (11.1%) | |
Data are n (%) and mean (SD). N is the total number of patients with available data. COVID-19 = coronavirus disease-2019. SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. CRRT = continuous renal replacement therapy. ECMO = extracorporeal membrane oxygenation. P values for comparing two groups were derived using Fisher's exact test for categorized variables and t-test for continuous variables. *Kaletra: Lopinavir and ritonavir.
#1 Admitted to the Third Affiliated Hospital of Sun Yat-Sen University in Guangzhou from January 22 to February 12, 2020, the last follow-up was on February 18, 2020.
#2 Diagnosed in Wuhan Jinyintan Hospital from January 1 to January 20, 2020, the last follow-up was on January 25, 2020.
NA, not available.